All tested patient sera and IVIG enhanced phagocytosis of the EB in a comparable manner. The presence of complement increased the uptake of beads, and yet this effect did not mask the influence of Eap on phagocytosis (Fig. 3b). As it is well known that Eap binds to cell surfaces, we ensured that EB were phagocytosed rather than attached to the cell surface: using immunofluorescence microscopy on parallel samples, it was demonstrated that in PBMC and granulocytes, EB were exclusively intracellularly located.

This finding contrasts with assays performed with endothelial cells where beads were found both intracellularly as well as on the cell surface (Fig. 4). This study demonstrated that anti-Eap antibodies are detectable in every tested healthy individual as well as in patients suffering selleck chemicals from acute and chronic S. aureus infections. We found that antibody titers were significantly Epigenetics Compound Library ic50 higher in patients

when compared with healthy controls. However, both groups showed a remarkable variability in titers, making it impossible to define a distinct cutoff. Therefore, the anti-Eap antibodies appear not to be suitable as a serological marker for the diagnosis or the prognosis of S. aureus infections. In accordance with our previous findings on eap transcription (Joost et al., 2009), here, we observed that patients with deep infections showed significantly higher anti-Eap titers than patients with superficial infection. Eap is known for its adhesive properties and has often been assigned a role in chronic infections (Lee et al., 2002; Harraghy et al., 2003; Athanasopoulos et al., 2006). We found that patients with long-lasting infections like abscesses or spondylodiscitis exhibited high antibody titers against Eap. Thymidylate synthase These findings imply that the concentration of Eap transcribed

within the infected tissue and the duration of the infection govern the subsequent antibody production. In contrast, the more acute manifestations of S. aureus disease in patients with bacteremia and sepsis were not associated with higher antibody titers than in patients with localized infections. In vitro, Eap has been shown to induce the production of interleukin-6 and tumor necrosis factor-α (Scriba et al., 2008), indicating a possible role of Eap in septic shock. However, the type and duration of antigen presentation is likely to be different in deep-seated tissue infections compared with sepsis; therefore, the contribution of Eap to the cytokine release associated with sepsis and the production of anti-Eap antibodies in the setting of more chronic, tissue-associated S. aureus infection may be seen as two sides of the same coin. To our knowledge, so far, only one other study has investigated antibodies in humans against Eap (also designated as Map) (Dryla et al., 2005a). In contrast to our results, Dryla and colleagues reported no differences between patients and controls.